Skip to main content

Table 3 Sensitivity analysis

From: Can polymorphisms of AMH/AMHR2 affect ovarian stimulation outcomes? A systematic review and meta-analysis

Outcome Polymorphism Comparison All studies MD (95%CI) I2 Sensitivity analysis Results
No. Studies/
participant
No. Studies/
participant
MD 95%CI I2
No. of oocytes retrieved AMH (rs10407022) TT versus GG/GT 6/1739 −0.19 (−1.29, 0.91) 81% a 5/1580 −0.82 (− 1.55, − 0.08) 52% Became significant
TT versus GG 3/792 0.25 (−2.70, 3.21) 93% a 2/687 −1.44 (−2.05, −0.83) 0% Became significant
TT versus GT 3/1199 −0.27 (−1.66, 1.12) 88% a 2/1052 −1.03 (− 1.87, − 0.19) 70% Became significant
GG versus TT/GT 3/1335 −0.42 (− 0.2.69, 1.85) 90% a 2/1176 0.71 (0.06, 1.53) 0% Became significant
AMHR (rs2002555) AA versus GG/AG 5/1614 0.01 (−0.81,0.83) 66% b 4/979 0.44 (−0.15, 1.02) 0% Not affected
AA versus GG 3/969 0.32 (−1.34, 1.99) 73% b 2/509 −0.53 (− 1.85, 0.79) 0% Not affected
AA versus AG 4/1587 −0.41 (−1.31, 0.48) 67% c 3/1056 −0.92 (−1.42, − 0.42) 0% Became significant
GG versus AA/AG 3/1342 −0.36 (−2.24, 1.53) 80% b 2/707 0.58 (−0.70, 1.87) 0% Not affected
Gn dosage AMHR (rs2002555) AA versus GG/AG 4/1230 −13.25 (−58.41, 32.47) 63% c 3/682 −53.36 (−146.58, 39.86) 44% Not affected
Stimulation duration AMHR (rs2002555) AA versus GG/AG 3/907 2.81 (−4.51, 10.13) 75% b 2/270 −0.27 (−0.86, 0.31) 66% Not affected
  1. a Sensitivity analysis excluding Peluso study
  2. b Sensitivity analysis excluding Wu study
  3. cSensitivity analysis excluding Cerra study
  4. AMH anti-Müllerian hormone, AMHR AMH receptor, Gn dosage gonadotropin consumption, MD weighted mean difference, No. number